Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension

European Respiratory Journal

Volumn 41, Issue 4, 2013, Pages 872-878

  Henkens, Ivo R ^a   Hazenoot, Thomas ^a,b   Boonstra, Anco ^b   Huisman, Menno V ^a   Vonk Noordegraaf, Anton ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antithrombotic therapy; Connective tissue disease; Safety

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; ENDOTHELIN RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SITAXSENTAN;

ABDOMINAL BLEEDING; ADULT; AGE DISTRIBUTION; ANEMIA; ANTIPHOSPHOLIPID SYNDROME; ARTERIOVENOUS MALFORMATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONNECTIVE TISSUE DISEASE; CONNECTIVE TISSUE DISEASE RELATED PULMONARY ARTERIAL HYPERTENSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIFFUSE LARGE HEMATOMA; DISEASE SEVERITY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAIRY CELL LEUKEMIA; HEART ANEURYSM; HEART RIGHT ATRIUM PRESSURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATOMA; HEMOPTYSIS; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; ISCHEMIC HEART DISEASE; LIFE TABLE; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SEX; SIDE EFFECT; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; THROMBOEMBOLISM; UROGENITAL BLEEDING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; HYPERTENSION, PULMONARY; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; VITAMIN K;

EID: 84875838231     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00039212     Document Type: Article

References (34)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Huber K, Beckmann R, Frank H, et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150: 929-933.
3. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12: 1446-1449.
4. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-458.
5. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130: 545-552.
6. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
7. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
8. Galie N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88S.
9. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
10. Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
11. Ogawa A, Matsubara H, Fujio H, et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension-anticoagulation and epoprostenol therapy. Circ J 2005; 69: 216-220.
12. Pulido T, Sandoval J, Roquet I, et al. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. Eur J Clin Invest 2009; 39: Suppl. 2, 14-18.
13. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
14. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-683.
15. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
16. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-2020.
17. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
19. Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32: 2282-2289.
20. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307.
21. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 650-656.
22. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004; 44: 1557-1566.
23. Nieto JA, Solano R, Ruiz-Ribo MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8: 1216-1222.
24. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
25. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of lowintensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
26. Delcroix M, Naeije R. Optimising the management of pulmonary arterial hypertension patients: emergency treatments. Eur Respir Rev 2010; 19: 204-211.
27. Zylkowska J, Kurzyna M, Pietura R, et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest 2011; 139: 690-693.
28. Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. Am J Gastroenterol 1998; 93: 1453-1456.
29. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
30. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
31. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 56S-61S.
32. Robbins IM, Kawut SM, Yung D, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 27: 578-584.
33. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
34. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.